Pharmacotherapeutic strategies for the treatment of anorexia nervosa - too much for one drug?
- 12 June 2020
- journal article
- review article
- Published by Taylor & Francis Ltd in Expert Opinion on Pharmacotherapy
- Vol. 21 (9), 1045-1058
- https://doi.org/10.1080/14656566.2020.1748600
Abstract
Introduction: Anorexia nervosa is a severe psychiatric illness and no medication has been approved for its treatment. This lack of biological treatments requires the development of new directions for pharmacological research. Areas covered: There is modest but emerging evidence that dopamine D2 and serotonin 1A and 2A receptor agonistic and antagonist medication might be beneficial for weight gain, although the underlying mechanisms are uncertain. Improving quality of life including treating comorbid conditions is an additional important outcome measure, but this has not been well researched. Biological and psychological risk factors together with neurobiological alterations during the illness maintain the disorder 's pathophysiology. Neuroscience research can be used to understand those interactions and advance the research agenda. The authors discuss the above as well as give perspectives on future research. Expert opinion: If a multidisciplinary approach that includes evidence-based psychotherapy shows unsatisfactory success in weight normalization and cognitive-emotional recovery, then more experimental treatments that are safe and have indicated treatment effectiveness should be tried to augment treatment. Identification and treatment of comorbid conditions to improve quality of life of the patient should also be part of the treatment regimen, even if the effect on weight gain is uncertain.Funding Information
- the National Institute of Mental Health (MH096777, MH103436)
This publication has 101 references indexed in Scilit:
- Impact of Physiologic Estrogen Replacement on Anxiety Symptoms, Body Shape Perception, and Eating Attitudes in Adolescent Girls With Anorexia NervosaBritish Journal of Psychology, 2013
- Dopaminergic control of cognitive flexibility in humans and animalsFrontiers in Neuroscience, 2013
- The need for complex ideas in anorexia nervosa: Why biology, environment, and psyche all matter, why therapists make mistakes, and why clinical benchmarks are needed for managing weight correctionInternational Journal of Eating Disorders, 2012
- A Double-Blind, Placebo-Controlled Study of Risperidone for the Treatment of Adolescents and Young Adults with Anorexia Nervosa: A Pilot StudyJournal of the American Academy of Child & Adolescent Psychiatry, 2011
- Olanzapine Use for the Adjunctive Treatment of Adolescents with Anorexia NervosaJournal of Child and Adolescent Psychopharmacology, 2011
- Infralimbic D2 Receptors Are Necessary for Fear Extinction and Extinction-Related Tone ResponsesBiological Psychiatry, 2010
- Microinfusion of the D1 receptor antagonist, SCH23390 into the IL but not the BLA impairs consolidation of extinction of auditory fear conditioningNeurobiology of Learning and Memory, 2008
- Psychopharmakotherapie mit Clomipramin und Paroxetin bei jugendlichen Patientinnen mit «Anorexia nervosa» und «Depressiver Episode» - eine Pilotstudie zu Verträglichkeit, Absetzquote und therapeutischen VerlaufskriterienZeitschrift für Kinder- und Jugendpsychiatrie und Psychotherapie, 2004
- Interactions between D1 and D2 dopamine receptor family agonists and antagonists: the effects of chronic exposure on behavior and receptor binding in rats and their clinical implicationsJournal of Neural Transmission, 1997
- Naltrexone use in the treatment of anorexia nervosa and bulimia nervosa*International Clinical Psychopharmacology, 1995